Cargando…
Increased serum kallistatin levels in type 1 diabetes patients with vascular complications
BACKGROUND: Kallistatin, a serpin widely produced throughout the body, has vasodilatory, anti-angiogenic, anti-oxidant, and anti-inflammatory effects. Effects of diabetes and its vascular complications on serum kallistatin levels are unknown. METHODS: Serum kallistatin was quantified by ELISA in a c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954956/ https://www.ncbi.nlm.nih.gov/pubmed/20860825 http://dx.doi.org/10.1186/2040-2384-2-19 |
_version_ | 1782187985315299328 |
---|---|
author | Jenkins, Alicia J McBride, Jeffrey D Januszewski, Andrzej S Karschimkus, Connie S Zhang, Bin O'Neal, David N Nelson, Craig L Chung, Jasmine S Harper, C Alex Lyons, Timothy J Ma, Jian-Xing |
author_facet | Jenkins, Alicia J McBride, Jeffrey D Januszewski, Andrzej S Karschimkus, Connie S Zhang, Bin O'Neal, David N Nelson, Craig L Chung, Jasmine S Harper, C Alex Lyons, Timothy J Ma, Jian-Xing |
author_sort | Jenkins, Alicia J |
collection | PubMed |
description | BACKGROUND: Kallistatin, a serpin widely produced throughout the body, has vasodilatory, anti-angiogenic, anti-oxidant, and anti-inflammatory effects. Effects of diabetes and its vascular complications on serum kallistatin levels are unknown. METHODS: Serum kallistatin was quantified by ELISA in a cross-sectional study of 116 Type 1 diabetic patients (including 50 with and 66 without complications) and 29 non-diabetic controls, and related to clinical status and measures of oxidative stress and inflammation. RESULTS: Kallistatin levels (mean(SD)) were increased in diabetic vs. control subjects (12.6(4.2) vs. 10.3(2.8) μg/ml, p = 0.007), and differed between diabetic patients with complications (13.4(4.9) μg/ml), complication-free patients (12.1(3.7) μg/ml), and controls; ANOVA, p = 0.007. Levels were higher in diabetic patients with complications vs. controls, p = 0.01, but did not differ between complication-free diabetic patients and controls, p > 0.05. On univariate analyses, in diabetes, kallistatin correlated with renal dysfunction (cystatin C, r = 0.28, p = 0.004; urinary albumin/creatinine, r = 0.34, p = 0.001; serum creatinine, r = 0.23, p = 0.01; serum urea, r = 0.33, p = 0.001; GFR, r = -0.25, p = 0.009), total cholesterol (r = 0.28, p = 0.004); LDL-cholesterol (r = 0.21, p = 0.03); gamma-glutamyltransferase (GGT) (r = 0.27, p = 0.04), and small artery elasticity, r = -0.23, p = 0.02, but not with HbA1c, other lipids, oxidative stress or inflammation. In diabetes, geometric mean (95%CI) kallistatin levels adjusted for covariates, including renal dysfunction, were higher in those with vs. without hypertension (13.6 (12.3-14.9) vs. 11.8 (10.5-13.0) μg/ml, p = 0.03). Statistically independent determinants of kallistatin levels in diabetes were age, serum urea, total cholesterol, SAE and GGT, adjusted r(2 )= 0.24, p < 0.00001. CONCLUSIONS: Serum kallistatin levels are increased in Type 1 diabetic patients with microvascular complications and with hypertension, and correlate with renal and vascular dysfunction. |
format | Text |
id | pubmed-2954956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29549562010-10-15 Increased serum kallistatin levels in type 1 diabetes patients with vascular complications Jenkins, Alicia J McBride, Jeffrey D Januszewski, Andrzej S Karschimkus, Connie S Zhang, Bin O'Neal, David N Nelson, Craig L Chung, Jasmine S Harper, C Alex Lyons, Timothy J Ma, Jian-Xing J Angiogenes Res Research BACKGROUND: Kallistatin, a serpin widely produced throughout the body, has vasodilatory, anti-angiogenic, anti-oxidant, and anti-inflammatory effects. Effects of diabetes and its vascular complications on serum kallistatin levels are unknown. METHODS: Serum kallistatin was quantified by ELISA in a cross-sectional study of 116 Type 1 diabetic patients (including 50 with and 66 without complications) and 29 non-diabetic controls, and related to clinical status and measures of oxidative stress and inflammation. RESULTS: Kallistatin levels (mean(SD)) were increased in diabetic vs. control subjects (12.6(4.2) vs. 10.3(2.8) μg/ml, p = 0.007), and differed between diabetic patients with complications (13.4(4.9) μg/ml), complication-free patients (12.1(3.7) μg/ml), and controls; ANOVA, p = 0.007. Levels were higher in diabetic patients with complications vs. controls, p = 0.01, but did not differ between complication-free diabetic patients and controls, p > 0.05. On univariate analyses, in diabetes, kallistatin correlated with renal dysfunction (cystatin C, r = 0.28, p = 0.004; urinary albumin/creatinine, r = 0.34, p = 0.001; serum creatinine, r = 0.23, p = 0.01; serum urea, r = 0.33, p = 0.001; GFR, r = -0.25, p = 0.009), total cholesterol (r = 0.28, p = 0.004); LDL-cholesterol (r = 0.21, p = 0.03); gamma-glutamyltransferase (GGT) (r = 0.27, p = 0.04), and small artery elasticity, r = -0.23, p = 0.02, but not with HbA1c, other lipids, oxidative stress or inflammation. In diabetes, geometric mean (95%CI) kallistatin levels adjusted for covariates, including renal dysfunction, were higher in those with vs. without hypertension (13.6 (12.3-14.9) vs. 11.8 (10.5-13.0) μg/ml, p = 0.03). Statistically independent determinants of kallistatin levels in diabetes were age, serum urea, total cholesterol, SAE and GGT, adjusted r(2 )= 0.24, p < 0.00001. CONCLUSIONS: Serum kallistatin levels are increased in Type 1 diabetic patients with microvascular complications and with hypertension, and correlate with renal and vascular dysfunction. BioMed Central 2010-09-22 /pmc/articles/PMC2954956/ /pubmed/20860825 http://dx.doi.org/10.1186/2040-2384-2-19 Text en Copyright ©2010 Jenkins et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Jenkins, Alicia J McBride, Jeffrey D Januszewski, Andrzej S Karschimkus, Connie S Zhang, Bin O'Neal, David N Nelson, Craig L Chung, Jasmine S Harper, C Alex Lyons, Timothy J Ma, Jian-Xing Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
title | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
title_full | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
title_fullStr | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
title_full_unstemmed | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
title_short | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
title_sort | increased serum kallistatin levels in type 1 diabetes patients with vascular complications |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954956/ https://www.ncbi.nlm.nih.gov/pubmed/20860825 http://dx.doi.org/10.1186/2040-2384-2-19 |
work_keys_str_mv | AT jenkinsaliciaj increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT mcbridejeffreyd increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT januszewskiandrzejs increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT karschimkusconnies increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT zhangbin increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT onealdavidn increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT nelsoncraigl increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT chungjasmines increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT harpercalex increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT lyonstimothyj increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications AT majianxing increasedserumkallistatinlevelsintype1diabetespatientswithvascularcomplications |